KT-474

CAT: 0804-HY-145483-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-145483-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
KT-474 (KYM-001; PROTAC IRAK4 degrader-7) is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL. KT-474 is a click chemistry reagent, containing an alkyne group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing azide groups[1][2][3].
CAS Number
[2432994-31-3]
Product Name Alternative
KYM-001; PROTAC IRAK4 degrader-7
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Apoptosis; IRAK; PROTACs
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; PROTAC
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/kt-474.html
Purity
99.77
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1N(C(CCC2=O)C(N2)=O)C3=CC=CC(C#CCOC(CC4)CCN4C[C@H]5CC[C@@](N(N=C6C(F)F)C=C6NC(C7=C(N=C(N8[C@@H](CO9)C[C@@H]9C8)C=C%10)N%10N=C7)=O)([H])CC5)=C3N1C
Molecular Formula
C44H49F2N11O6
Molecular Weight
865.93
Precautions
H302, H315, H319
References & Citations
[1]Nello Mainolfi, et al. Irak degraders and uses thereof. Patent WO2020113233A1.|[2]Ackerman L, et al. IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial. Nat Med. 2023 Dec;29 (12) :3127-3136.|[3]Joseph F. Kelleher, et al. Abstract LB-272: KYM-001, a first-in-class oral IRAK4 protein degrader, induces tumor regression in xenograft models of MYD88-mutant ABC DLBCL alone and in combination with BTK inhibition. Cancer Res (2019) 79 (13_Supplement) : LB-272.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
IRAK4

Popular Products